Eli Lilly and Company has signed an agreement with MeiraGTx Holdings plc that grants Lilly global exclusive rights to MeiraGTx’s investigational gene therapy for a severe inherited retinal condition. The centerpiece of the deal is the programme...
Roche’s experimental multiple sclerosis (MS) drug fenebrutinib has reached a major milestone, meeting its main goal in one of two late-stage trials for relapsing MS. The treatment sharply reduced annualised relapse rates over 96 weeks compared with..
Positive results from the pivotal LIBERTY-AFRS-AIMS Phase 3 trial reveal that Dupixent considerably enhanced symptoms in adults and children aged six years and older with allergic fungal rhinosinusitis (AFRS). The investigational treatment met...
Bayer’s Kerendia™ (finerenone) approved in India for HFpEF/HFmrEF, offering dual heart-kidney protection and improving outcomes in high-risk cardiovascular patients.
For the first time, Sun Pharmaceutical has seen its U.S. sales of innovative medicines overtake generics in the second quarter of FY26, marking a major shift for India’s largest drug maker. The surge came on the back of strong sales of Ilumya...
Zydus Lifesciences Limited has been provisionally granted by the US FDA to its 4mg Budesonide a delayed release capsule which is a move that would make the company broaden its market in the U.S. generics sector...
Expressions of interest (EoI) have been invited by the Indian Council of Medical Research (ICMR) to firms, manufacturers and research organizations that have the capability to develop and produce monoclonal antibodies (mAbs) against Nipah virus...
Roche today reported positive Phase III results for Gazyva (obinutuzumab) in adults with systemic lupus erythematosus (SLE) receiving standard therapy. The ALLEGORY study met its main goal, showing more patients achieved a four-point improvement...
Takeda has completed its seven-year Phase 3 TIDES trial of QDENGA confirming that the vaccine provides lasting and reliable protection against dengue. The study, which also looked at the effects of a booster dose, showed that QDENGA maintains...
Johnson & Johnson MedTech, a cardiac arrhythmia treatment global leader, said that new clinical and real-world results of its VARIPULSE™ Platform in pulsed field ablation (PFA) of atrial fibrillation (AF) would be revealed at the Asia Pacific...
, CDSCO.jpg)